World's Best Scientists 2026 revealed!
Martin Bornhäuser

Martin Bornhäuser

D-Index & Metrics

Medicine

D-Index
109
Citations
46267
World Ranking
5754
National Ranking
322

Overview

Martin Bornhäuser is affiliated with TU Dresden in Germany and has a significant body of research primarily focused on medical sciences. Their work spans several subfields including hematology, molecular biology, genetics, oncology, and public health, environmental and occupational health. The primary domain of expertise is medicine, with a particular emphasis on hematological malignancies.

Their research covers multiple topics, notably:

  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Chronic Myeloid Leukemia Treatments
  • Cancer Genomics and Diagnostics

Bornhäuser has contributed extensively to publications in various scientific venues, with frequent appearances in:

  • Blood (66 publications)
  • Bone Marrow Transplantation (20 publications)
  • Leukemia (17 publications)
  • HemaSphere (16 publications)
  • Blood Advances (13 publications)

Frequent co-authors who have collaborated with Bornhäuser include:

  • Christoph Röllig (126 collaborations)
  • Uwe Platzbecker (113 collaborations)
  • Hubert Serve (92 collaborations)
  • Johannes Schetelig (88 collaborations)
  • Jan Moritz Middeke (85 collaborations)

Among recent scientific papers associated with the field and relevant to their research interests are:

  • Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN), 2020, Journal of Clinical Oncology
  • Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia, 2020, Science Translational Medicine
  • Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update, 2021, Frontiers in Cell and Developmental Biology
  • CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome, 2021, Blood
  • Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML, 2021, Blood

Best Publications

  • Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

    Christian Thiede;Christine Steudel;Brigitte Mohr;Markus Schaich

  • Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

    Joachim Oswald;Sabine Boxberger;Birgitte Jørgensen;Silvia Feldmann

  • Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger

  • Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party

    Christoph Schmid;Myriam Labopin;Arnon Nagler;Martin Bornhäuser

  • Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

    Andreas Burchert;Gesine Bug;Lea V. Fritz;Jürgen Finke

  • Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

    Nicolaus Kröger;Ernst Holler;Guido Kobbe;Martin Bornhäuser

  • Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

    Sally Arai;Mukta Arora;Tao Wang;Tao Wang;Stephen R. Spellman

  • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    Christoph Röllig;Hubert Serve;Andreas Hüttmann;Richard Noppeney

  • Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL)

    Barbara Wassmann;Heike Pfeifer;Nicola Goekbuget;Dietrich W. Beelen

  • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

    Platzbecker U;Wermke M;Radke J;Oelschlaegel U

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation

    Roy F. Chemaly;Andrew J. Ullmann;Susanne Stoelben;Marie Paule Richard

  • Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

    Gérard Socié;Claudia Schmoor;Wolfgang A. Bethge;Hellmut D. Ottinger

  • Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

    M von Bonin;F Stölzel;A Goedecke;K Richter

  • Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

    J. Schetelig;C. Thiede;M. Bornhäuser;R. Schwerdtfeger

  • Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

    A Ehninger;M Kramer;C Röllig;C Thiede

  • Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection.

    C Thiede;M Florek;M Bornhäuser;M Ritter

  • Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

    Uwe Platzbecker;Jan Moritz Middeke;Katja Sockel;Regina Herbst

  • Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

    Martin Bornhäuser;Joachim Kienast;Rudolf Trenschel;Andreas Burchert

  • Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

    Christoph Röllig;Martin Bornhäuser;Christian Thiede;Franziska Taube

Frequent Co-Authors

Marc Schmitz
Marc Schmitz TU Dresden
Nicolaus Kröger
Nicolaus Kröger Universität Hamburg
Michael Bachmann
Michael Bachmann Helmholtz-Zentrum Dresden-Rossendorf
Hubert Serve
Hubert Serve Goethe University Frankfurt
Jürgen Finke
Jürgen Finke University of Freiburg
Carsten Werner
Carsten Werner Leibniz-Institut für Polymerforschung Dresden e. V.
Hermann Einsele
Hermann Einsele University of Würzburg
Wolfgang E. Berdel
Wolfgang E. Berdel University of Münster

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative medical education pathways can offer greater flexibility for students with varying backgrounds or schedules. Many registered nurses looking to advance their careers consider the rn to bsn online without clinicals option. This pathway is ideal for employed RNs who wish to earn a bachelor’s degree without having to complete additional hands-on clinical hours.

For those seeking advanced practice roles, the demand for accelerated dnp programs online has increased. These programs allow students to complete doctoral-level studies rapidly, helping them enter leadership or specialist positions faster. In addition, some students prefer dnp programs without dissertation, which eliminate the intensive research component, focusing instead on practical leadership skills required in the healthcare setting.

If you’re just starting on your nursing journey, the fastest lpn program options are worth considering. These fast-track options provide a quick pathway into the workforce, making them attractive for those eager to begin careers in patient care. Online degrees and diverse program designs are shaping new, flexible paths toward advancement in medicine and healthcare.

Best Scientists Citing Martin Bornhäuser

Trending Scientists

Recently Published Articles